low-molecular-weight heparin

Also found in: Dictionary, Wikipedia.

low-molecular-weight heparin (LMWH)

a class of drugs used to prevent potentially fatal blood clots in patients undergoing surgery or patients at risk for blood clots. It has been used to prevent deep vein thrombosis in patients undergoing hip and knee replacements. LMWH has an advantage over regular heparin in that predictable plasma levels are achieved, obviating the need for regular monitoring of prothrombin time and partial thromboplastin time.
References in periodicals archive ?
Low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
He highlighted a European analysis of six phase III clinical trials totaling more than 27,000 patients with venous thromboembolism (VTE) in which dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), or edoxaban (Savaysa) was compared to the traditional strategy of unfractionated or low-molecular-weight heparin (LMWH) bridging to warfarin or another vitamin K antagonist.
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
The investigators were able to reproduce the rule by applying it to data from two randomized controlled trials that compared a low-molecular-weight heparin with a vitamin K antagonist, Dr.
Houde JP, Steinberg G 1999 Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty Journal of Arthroplasty 14 (3) 372-374
The authors conducted a literature search to identify randomized trials that compared unfractionated heparin with control, low-molecular-weight heparin with control, low-molecular-weight heparin with unfractionated heparin, or a selective factor Xa inhibitor (fondaparinux) with placebo for reducing DVT, pulmonary embolism (PE), or mortality in hospitalized medical patients.
Low-molecular-weight heparin was designed to behave more predictably in the body, thereby making monitoring unnecessary.
Location was unaffected by the use of low-molecular-weight heparin vs.
have reached an agreement in which the latter will market Fragmin, a low-molecular-weight heparin in the United States.
Low-molecular-weight heparin - An opportunity for home treatment of venous thrombosis.
In the standard therapy arm, once patients were off low-molecular-weight heparin and on warfarin they were within the target INR 58% of the time.

Full browser ?